NEUROPHARMACOLOGY OF COGNITION AND MOOD IN GERIATRIC NEUROPSYCHIATRY

老年神经精神病学中认知和情绪的神经药理学

• 批准号: 3880834
• 负责人: T SUNDERLAND
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3880834
• 关键词: Alzheimer's disease; MAO inhibitors; aging; amphetamines; anticholinergic agent; behavior test; brain disorder chemotherapy; cholinergic agents; clinical depression; cognition; combination chemotherapy; dementia; deprenyl; diagnosis design /evaluation; diagnosis quality /standard; drug adverse effect; drug design /synthesis /production; human old age (65+); human subject; human therapy evaluation; human tissue; longitudinal human study; memory disorders; neuropharmacology; neuropsychological tests; physostigmine; piperazines; psychobiology; psychopharmacology; questionnaires; scopolamine; thyrotropin releasing hormone

New therapeutic approaches are desperately needed in Alzheimer's disease research. Therefore, our research program over the past year has focused on the use of pharmacologic agents in innovation therapeutic and drug challenge strategies. We have continued to study the cognitive and behavioral effects of the anticholinergic agent, scopolamine and have attempted to better understand its antimemory effects. By combining scopolamine with the tripeptide, thyrotropin releasing hormone (TRH), or the stimulant, amphetamine, we are dissecting the various components of this pharmacologic challenge strategy. We have discovered that a significant part of scopolamine's amnestic effect can be reversed with these drugs, thus demonstrating that other non-cholinergic processes are involved in memory and cognition. These findings are being pursued in a new generation of challenge studies which win help identify those other processes. From a complementary perspective, the Unit is also developing new stra- tegies in therapeutic drug trials of Alzheimer's Disease patients. Building on our previous work which showed that the monoamine oxidase inhibitor, 1-deprenyl, was helpful in the symptomatic treatment of this disorder, we are now going on to investigate potentially neuroprotective effects of 1-deprenyl in Alzheimer patients during long-term trials. We are also attempting to expand the horizon of dementia therapies by combining dif- ferent pharmacologic agents in a single therapeutic trial. Our ongoing study of combination therapies (eg. physostigmine with 1-deprenyl) is the first such attempt at pharmacologic synergy in Alzheimer's Disease and, if successful may well represent a new therapeutic strategy for the 1990's.

阿尔茨海默氏病迫切需要新的治疗方法 研究。因此，过去一年中我们的研究计划集中在 在创新治疗和药物中使用药理学剂 挑战策略。我们继续研究认知和 抗胆碱能剂，scopolamine的行为影响，并具有 试图更好地理解其抗性效应。通过组合 西pol碱与三肽，甲状腺激素释放激素（TRH）或 兴奋剂，苯丙胺，我们正在解剖 这种药理挑战策略。我们发现一个 Scopolamine的重要部分可以逆转 这些药物，因此表明其他非胆碱能过程是 参与记忆和认知。这些发现是在新的 赢得挑战研究的产生有助于识别其他人 过程。 从互补的角度来看，该部门还在开发新的策略 阿尔茨海默氏病患者的治疗药物试验中的Tegies。建筑 关于我们以前的工作，表明单胺氧化酶抑制剂， 1-肾上腺素有助于对这种疾病的有症状治疗，我们 现在正在研究 长期试验期间，阿尔茨海默氏症患者中的1-肾上腺素。我们也是 试图通过结合差异来扩大痴呆疗法的视野 在一次治疗试验中，药物药物剂。我们正在进行的 组合疗法研究（例如，具有1-肾上腺素的物理学）是 首先尝试在阿尔茨海默氏病中进行药理学协同作用，如果 成功可能代表了1990年代的新治疗策略。